The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review

Scientific Reports
Wei YanBei He

Abstract

Emerging evidence indicates that FHIT is a candidate tumor suppressor in non-small cell lung cancer (NSCLC). However, the correlation between FHIT hypermethylation and clinicopathological characteristics of NSCLC remains unclear. Thus, we conducted a meta-analysis to quantitatively evaluate the effects of FHIT hypermethylation on the incidence of NSCLC and clinicopathological characteristics. Final analysis of 1717 NSCLC patients from 16 eligible studies was performed. FHIT hypermethylation was found to be significantly higher in NSCLC than in normal lung tissue, the pooled OR from 8 studies including 735 NSCLC and 708 normal lung tissue, OR = 5.45, 95% CI = 2.15-13.79, p = 0.0003. FHIT hypermethylation was also correlated with sex status, smoking status, as well as pathological types. We did not find that FHIT hypermethylation was correlated with the differentiated types or clinical stages in NSCLC patients. However, patients with FHIT hypermethylation had a lower survival rate than those without, HR = 1.73, 95% CI = 1.10-2.71, p = 0.02. The results of this meta-analysis suggest that FHIT hypermethylation is associated with an increased risk and worsen survival in NSCLC patients. FHIT hypermethylation, which induces the inacti...Continue Reading

References

Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Jun 30, 1996·Statistics in Medicine·R DerSimonian
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Jul 22, 1998·Proceedings of the National Academy of Sciences of the United States of America·Y PekarskyC M Croce
Nov 15, 2002·Cancer Biology & Therapy·Yuri PekarskyCarlo M Croce
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Sep 19, 2003·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Chih-Yi HsuHung Chiang
Sep 3, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ching TzaoYi-Ching Wang
Nov 16, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yoshio TomizawaMasatomo Mori
Mar 28, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Eun Ju LeeDuk-Hwan Kim
Oct 5, 2006·International Journal of Cancer. Journal International Du Cancer·Joshua P CantorKay Huebner
May 29, 2007·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Dong-Sun KimJae Yong Park
Jul 4, 2007·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Naoki YanagawaTeiichi Motoyama
Feb 27, 2008·Virchows Archiv : an International Journal of Pathology·Naoki YanagawaTeiichi Motoyama
Mar 6, 2008·The Journal of Biological Chemistry·Francesco TrapassoCarlo M Croce
Dec 18, 2008·Future Oncology·Flavia PichiorriCarlo M Croce
Dec 20, 2008·American Journal of Respiratory and Critical Care Medicine·Carla VerriUNKNOWN EUELC Consortium
Jul 23, 2009·Proceedings of the National Academy of Sciences of the United States of America·Alessandro RimessiRosario Rizzuto
Dec 25, 2009·Journal of Cancer Research and Clinical Oncology·Md Imtaiyaz HassanFaizan Ahmad
Jun 22, 2010·TheScientificWorldJournal·Anjilna Wali
Sep 20, 2011·Cellular and Molecular Neurobiology·Gulsah CecenerSahsine Tolunay
Jan 13, 2012·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Mar 20, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Francesca AndrianiLuca Roz
Mar 28, 2012·The Journal of Pathology·Irene RomeroAngel M Garcia-Lora
Apr 12, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P GuoK Li
Mar 16, 2013·International Journal of Clinical Oncology·Chiaki BanzaiUNKNOWN Gynecological Cancer Registry of Niigata
Jun 12, 2013·Epigenomics·Xiaotu MaAdi F Gazdar
Jun 26, 2013·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Rabeah Abbas Al-TemaimiFahd Al-Mulla
Jul 23, 2013·International Journal of Molecular Sciences·Yannick DelpuJérôme Torrisani
Aug 24, 2013·Expert Review of Respiratory Medicine·Michael FleischhackerBernd Schmidt
Jun 18, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Riham Abdel-Hamid HarounKamal Ali Shalaby

❮ Previous
Next ❯

Citations

Aug 15, 2018·American Journal of Respiratory and Critical Care Medicine·Svenja Dannewitz ProssedaEdda Spiekerkoetter
Sep 1, 2016·PloS One·Yushun GaoShugeng Gao
Mar 28, 2017·Endocrine-related Cancer·Georgios K DimitriadisAshley Grossman
Jun 24, 2017·International Journal of Environmental Research and Public Health·Di LiuYouxin Wang

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
xenograft
xenografts

Software Mentioned

STATA
Review Manager

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Related Papers

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Chen-Guo ZhengZong-Jing Chen
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Kaize ZhongJian Zhao
© 2022 Meta ULC. All rights reserved